Warning letter
Kabco Pharmaceuticals, Inc. [ARCHIVED]: warning letter of Nov 10, 2010
FDA warning letter 129615 · New York District Office
Key facts
| Reference number | 129615 |
|---|---|
| Company | Kabco Pharmaceuticals, Inc. [ARCHIVED] |
| Subject | CGMP in Manufacturing, Packing, Labeling, or Holding Operations for Dietary Supplements/Adulterated |
| Issue date | Nov 10, 2010 |
| Posted date | Nov 10, 2010 |
| Issuing office | New York District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 111.75(a), 111.123(b)(2), 111, 111.260, 111.453, 111.475, 111.27(a)(5)(i), 111.35(b)(2), 111.70(e), 111.123(b)(1), 111.210(a), 111.210(c) and 4 more |
| Inspection city | Amityville |
| Inspection ZIP | 11701 |
| Inspection start date | Jun 21, 2010 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: